Literature DB >> 15454923

Interplay of natural killer cells and their receptors with the adaptive immune response.

David H Raulet1.   

Abstract

Although natural killer (NK) cells are defined as a component of the innate immune system, they exhibit certain features generally considered characteristic of the adaptive immune system. NK cells also participate directly in adaptive immune responses, mainly by interacting with dendritic cells. Such interactions can positively or negatively regulate dendritic cell activity. Reciprocally, dendritic cells regulate NK cell function. In addition, 'NK receptors' are frequently expressed by T cells and can directly regulate the functions of these cells. In these distinct ways, NK cells and their receptors influence the adaptive immune response.

Mesh:

Substances:

Year:  2004        PMID: 15454923     DOI: 10.1038/ni1114

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  109 in total

Review 1.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

2.  Activation or tolerance of natural killer cells is modulated by ligand quality in a nonmonotonic manner.

Authors:  Jayajit Das
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

3.  Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Authors:  Eric Luedke; Alena Cristina Jaime-Ramirez; Neela Bhave; Julie Roda; Moaz Maqbool Choudhary; Bhavna Kumar; Theodoros N Teknos; William E Carson
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

4.  IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

Authors:  Elizabeth L McMichael; Alena Cristina Jaime-Ramirez; Kristan D Guenterberg; Eric Luedke; Lakhvir S Atwal; Amanda R Campbell; Zhiwei Hu; Armika S Tatum; Sri Vidya Kondadasula; Xiaokui Mo; Susheela Tridandapani; Mark Bloomston; E Christopher Ellison; Terence M Williams; Tanios Bekaii-Saab; William E Carson
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

5.  IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis.

Authors:  M T Isla Larrain; M E Rabassa; E Lacunza; A Barbera; A Cretón; A Segal-Eiras; M V Croce
Journal:  Tumour Biol       Date:  2014-04-01

6.  Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Authors:  Elizabeth L McMichael; Nicholas B Courtney; Megan C Duggan; Robert Wesolowski; Dionisia Quiroga; Sri Vidya Kondadasula; Lakhvir S Atwal; Neela Bhave; Eric Luedke; Alena Cristina Jaime-Ramirez; Amanda R Campbell; Xiaokui Mo; John C Byrd; William E Carson Iii
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

Review 7.  Multiple hats for natural killers.

Authors:  Kevin Ramirez; Barbara L Kee
Journal:  Curr Opin Immunol       Date:  2010-03-23       Impact factor: 7.486

8.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

9.  Spectrum and clinical implications of syntaxin 11 gene mutations in familial haemophagocytic lymphohistiocytosis: association with disease-free remissions and haematopoietic malignancies.

Authors:  E Rudd; K Göransdotter Ericson; C Zheng; Z Uysal; A Ozkan; A Gürgey; B Fadeel; M Nordenskjöld; J-I Henter
Journal:  J Med Genet       Date:  2006-04       Impact factor: 6.318

Review 10.  NK cells, autoantibodies, and immunologic infertility: a complex interplay.

Authors:  Caterina De Carolis; Carlo Perricone; Roberto Perricone
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.